Our RNA sequencing and analytics offer the most comprehensive view of the transcriptome for research studies. Identify novel transcripts and isoforms, quantify (differential) expression, alternative splice sites, long non-coding RNAs, fusion genes, etc. [more]

Exome and gene panel sequencing offer a cost-effective alternative to whole genome sequencing and cover the majority of disease-linked mutations in the human genome. With the option to offer clinical decision support reports, Svastia offers an end-to-end solution for cancer treatment selection and relapse prediction [more]

RNA Sequencing and Analytics

Our RNA sequencing and analytics offer the most comprehensive view of the transcriptome for research studies: Identify novel transcripts and isoforms, quantify (differential) expression, alternative splice sites, long non-coding RNAs, fusion genes, etc.

Product features:

Platform: Illumina or other platforms depending upon request
Libraries: Illumina TruSeq RNA Library prep, or others
Sample requirements: Get in touch

Use cases with bundled bioinformatics analysis:

  • Gene expression changes between sensitive/resistant cell lines
  • Tumor subtype classification
  • Expression of drug target(s) and the genes in the pathways
  • Pathological mechanisms

    • Exome and Gene Panel Sequencing

    Exome and gene panel sequencing offer a cost-effective alternative to whole genome sequencing and cover the majority of disease-linked mutations in the human genome. Our comprehensive exome sequencing offer.

    Product offer:

    Library: Agilent SureSelect V6 or Twist Biosciences
    Sequencing: Illumina platform, paired-end, 180~280bp DNA library
    Data quality: Guaranteed data quality >75% reads with mapping quality score > Q30, that meets Illumina’s guarantee
    Turn-around time: 3 to 4 weeks, including data analysis
    Sample requirements: Fresh sample: ~0.6μg (a minimum of 200μg acceptable with risk); FFPE: >= 1μg (stringent sample QC is required); DNA Concentration: >=20μg/ml; DNA volume: >=20μl; OD260/280 = 1.8 to 2.0 with no sample degradation or contamination
    Sequencing depth: 50-100x for Mendelian/rare diseases, 200x for Svastia’s clinical decision support for cancer treatment selection

    Bioinformatics

    Standard: Data QC, mapping with reference genome, SNPs/INDELs using a multi-software variant calling workflow, with statistics and annotation
    Advanced: CNVs, Structural Variants with annotation, Network and pathway analysis
    Clinical Reports for Oncology: Standard for all cancer samples, with inclusive pricing across all product offers

    T/B-Cell Receptor Sequencing

    We have developed novel analytical workflows for monitoring TCR/BCR repertoires to enable biomarker-aided immune-oncology and COVID-19 therapies. These will serve as indicative biomarkers to assess the disease progression or the efficacy of vaccines or therapies under development.

    COVID-19 offer:

  • Next-generation sequencing, assembly and annotation of Ig variable regions, mainly the differences in CDR3s before/after vaccination.
  • Identification of potentially neutralizing SARS-CoV-2 antibodies for therapy development
  • Estimation of TCRs or BCRs post therapy to ensure expected immunity against repetitive SARS-CoV-2 positive status

    • SNP Arrays

    Our low-cost GSA array offer is perfect for genotyping samples at scale, and for its versatile use in sample quality control, tracking, and minimalistic genotype-based overview for disease analysis.

    Please get in touch with us Contact Form